SR17018 is primarily researched for its potential therapeutic applications in the field of neuroscience and pharmacology. It is known to act as a selective agonist for the sigma-1 receptor, which plays a significant role in modulating various cellular processes, including neuroprotection, cognition, and mood regulation.

In preclinical studies, SR17018 has shown promise in treating neurodegenerative diseases such as Alzheimer's and Parkinson's by enhancing neuronal survival and reducing neuroinflammation. Additionally, it is being explored for its potential to alleviate symptoms of depression and anxiety due to its ability to modulate neurotransmitter systems involved in mood regulation.

Its application in pain management is also under investigation, particularly for chronic pain conditions, where it may help in reducing pain perception and improving patient outcomes. Overall, SR17018 represents a promising candidate for developing novel treatments for a range of neurological and psychiatric disorders.